Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.62 |
| ▸ | TK1 | P04183 | 5/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | ALB | P02768 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | TK2 | O00142 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15354282 | 1.00 | RNASE1 (0.62) | RNASE1TK1LMNATSHRALB | |
| SCHEMBL25747162 | 1.00 | RNASE1 (0.62) | RNASE1TK1LMNATSHRALB | |
| SCHEMBL25797545 | 1.00 | RNASE1 (0.62) | RNASE1TK1LMNATSHRALB | |
| SCHEMBL24059196 | 1.00 | RNASE1 (0.62) | RNASE1TK1LMNATSHRALB | |
| SCHEMBL733403 | 1.00 | RNASE1 (0.62) | RNASE1TK1LMNATSHRALB | |
| SCHEMBL24059145 | 1.00 | RNASE1 (0.62) | RNASE1TK1LMNATSHRALB | |
| SCHEMBL8424862 | 0.92 | RNASE1 (0.53) | RNASE1TK1LMNAALBPKM | |
| SCHEMBL8424863 | 0.92 | RNASE1 (0.53) | RNASE1TK1LMNAALBPKM | |
| SCHEMBL10079072 | 0.91 | TOP2A (0.54) | RNASE1TK1 | |
| SCHEMBL14788961 | 0.91 | TOP2A (0.54) | RNASE1TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12398170-B2 | Nucleoside derivative and use thereof | NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (JP) | 2025-08-26 | — | — | US | disclosed |
| US-20250215040-A1 | METHOD AND COMPOUND | ATDBio Limited (GB) | 2025-07-03 | — | — | US | disclosed |
| US-12202848-B2 | Phosphoramidite activator | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2025-01-21 | — | — | US | disclosed |
| US-20240166674-A1 | PHOSPHORAMIDITE ACTIVATOR | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2024-05-23 | — | — | US | disclosed |
| CN-114555617-B | Phosphoramidite activators | 富士胶片和光纯药株式会社 | 2024-03-08 | — | — | CN | disclosed |
| EP-4047004-B1 | PHOSPHORAMIDITE ACTIVATOR | FUJIFILM WAKO PURE CHEMICAL CORP (JP) | 2024-03-06 | — | — | EP | disclosed |
| WO-2024010870-A2 | CRYSTALLINE MONOMERS FOR PREPARING ANTISENSE OLIGONUCLEOTIDES AND METHODS OF THEIR PREPARATION AND USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-01-11 | — | — | WO | disclosed |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| WO-2023178133-A9 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023180237-A1 | METHOD AND COMPOUND | ATDBio Limited (GB) | 2023-09-28 | — | — | WO | disclosed |
| US-5218102-A | Easily synthesized, hybridize well with target sequences | IMPROBIO (BE) | 1993-06-08 | — | — | US | disclosed |
| EP-0541722-A1 | COMPOUNDS AND METHODS FOR INHIBITING GENE EXPRESSION. | STERLING WINTHROP INC (US) | 1993-05-19 | — | — | EP | disclosed |
| WO-1993006120-A1 | PHOSPHORAMIDATE ANALOGS OF 5-FLUORO-2'-DEOXYURIDINE | UNIVERSITY OF ROCHESTER (US) | 1993-04-01 | — | — | WO | disclosed |
| US-5192749-A | Viricide, AIDS | SYNTEX (U.S.A.) INC. (US) | 1993-03-09 | — | — | US | disclosed |
| WO-1992013869-A1 | METHYLENE PHOSPHONATE NUCLEOSIDE ANALOGS AND OLIGONUCLEOTIDE ANALOGS MADE THEREFROM | GILEAD SCIENCES, INC. (US) | 1992-08-20 | — | — | WO | disclosed |
| WO-1992002534-A2 | COMPOUNDS AND METHODS FOR INHIBITING GENE EXPRESSION | STERLING DRUG, INC. (US) | 1992-02-20 | — | — | WO | disclosed |
| US-5026838-A | Starting materials for polynucleotides | NIPPON ZEON CO., LTD. (JP) | 1991-06-25 | — | — | US | disclosed |
| US-4914193-A | INTERMEDIATES FOR OLIGODEOXYNUCLEOTIDES | TOAGOSEI CHEMICAL INDUSTRY CO., LTD. (JP) | 1990-04-03 | — | — | US | disclosed |
| EP-0334694-A1 | Nucleic acid probes with non-radioactive labels, and preparation processes | LA REGION WALLONNE (BE) | 1989-09-27 | — | — | EP | disclosed |
| EP-0216357-A2 | Phosphoramidite compounds and process for production thereof | NIPPON ZEON CO., LTD. (JP) | 1987-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | RNASE1 3/4885TK1 37/4885LMNA 2032/4885 |
| US-20240166674-A1 | PHOSPHORAMIDITE ACTIVATOR | ITPA, INPP5D, INPP5B | RNASE1 1474/4885TK1 101/4885LMNA 4192/4885 |
| US-12398170-B2 | Nucleoside derivative and use thereof | NT5C3B, NUDT1, PNP | RNASE1 269/4885TK1 327/4885LMNA 3363/4885 |
| US-12202848-B2 | Phosphoramidite activator | ITPA, INPP5D, INPP5B | RNASE1 1474/4885TK1 101/4885LMNA 4192/4885 |
| US-20250215040-A1 | METHOD AND COMPOUND | POLN, POLRMT, FBL | RNASE1 38/4885TK1 322/4885LMNA 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.